Skip to main content
. Author manuscript; available in PMC: 2016 Apr 11.
Published in final edited form as: Cancer Sci. 2016 Feb 10;107(3):359–368. doi: 10.1111/cas.12859

Figure 1.

Figure 1

I-branching N-acetylglucosaminyltransferase (GCNT2) expression correlates with prostate cancer (PCa) progression. (A) Biosynthetic pathways for I-antigen. (B) Expression level of GCNT2 was determined using quantitative polymerase chain reaction analysis. (C) PCa specimens were stained with an anti-GCNT2 antibody followed by staining with a horseradish peroxidase-conjugated secondary antibody. Counterstaining was performed using hematoxylin and eosin. GCNT2-positive cancer cells are indicated in brown. (D) Prostate-specific antigen-free survival periods were compared between GCNT2-positive and GCNT2-negative specimens, and survival analysis was conducted using Kaplan–Meier curves. Scale bars: 200 μm.